FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Carbetapentane Citrate Removed from Regs

[ Price : $8.95]

Federal Register Final rule: FDA removes entries for carbetapentane citrate from its drug regulations because it had been determin...

Consumers Dont Trust FDA to Keep BTC Safe

[ Price : $8.95]

A survey says consumers support making some drugs available behind the counter, but dont believe FDA can ensure their safety.

FTC Settles Ovcon Case Against Barr

[ Price : $8.95]

Barr Laboratories agrees not to accept payments from branded drug companies in return for delaying generic drugs from entering the...

DDMAC Hits the Ground Running with Ad Reviews

[ Price : $8.95]

DDMAC says it has received 18 DTC ad review submissions under the FDA Amendments Act user fee provision, while 31 entities commit ...

Its Official, OIA Stripped of Internal Probes

[ Price : $8.95]

Effective 11/30, FDAs Office of Internal Affairs loses its authority to investigate agency employees for alleged criminal miscondu...

FDA OKs Expanded Use for Cymbalta

[ Price : $8.95]

FDA approves an Eli Lilly supplemental NDA for Cymbalta and its use for maintenance treatment of major depressive disorder in adul...

FDA Grants Arimidex Pediatric Exclusivity

[ Price : $8.95]

FDA approves six-months pediatric exclusivity for AstraZenecas Arimidex.

Pipex Pharmaceuticals NDA for Wilsons Disease

[ Price : $8.95]

Pipex Pharmaceuticals files an NDA for Coprexa, indicated for treating Wilsons disease.

FDA Accepts UCB NDA for Diabetic Pain

[ Price : $8.95]

FDA accepts for review a UCB NDA for Vimpat (lacosamide), indicated for treating diabetic neuropathic pain.

Senator Investigating Avastin Availability

[ Price : $8.95]

Sen. Herb Kohl asks FDA for detailed information on Genentechs decision to limit availability of its Avastin to certain compoundin...